- Across 13 real-world switch studies evaluating more than 800 IBD patients
- In 5 real-word studies evaluating more than 400 IBD patients
- Across 10 real-world studies evaluating more than 550 IBD patients
ECCO Position Statement on Biosimilars – Danese S, et al. J Crohns Colitis 20175.
Click below to read more about Inflectra® evidence in IBD:
†Remicade® is a registered trademark of MSD.
IBD, Inflammatory bowel disease; ECCO, European Crohn's and Colitis Organisation.
PP-IFA-GBR-0308. December 2018